Internal tandem duplications in FMS-like tyrosine kinase-3 (FLT3-ITD) and mutations in nucleophosmin-1 (NPM1) are present in 20% and 30% of all AML patients, respectively, and they can change the evolution of the disease [31,32]. The gene discussed is NPM1; the disease is acute myeloid leukemia.